PanGen Biotech Reports Q3 Revenue of KRW 3.97 Billion Amid Strong EPO Biosimilar Export Growth
November 13.2026
PanGen Biotech Reports Q3 Revenue of KRW 3.97 Billion Amid Strong EPO Biosimilar Export Growth
- Top-line momentum driven by robust EPO biosimilar exports -
- Temporary operating ..